Elevation Oncology to be acquired by Concentra for $0.36/share plus CVR; CEO Ferra out

Elevation Oncology, Inc.

Merger with Concentra Biosciences: $0.36 cash per share plus contingent value right (CVR) for up to 80% of net proceeds from EO-1022.
Board unanimously recommends tender; closing requires minimum $26.4M net cash and tender of >50% of outstanding shares.
CEO Joseph Ferra terminated effective June 30; CFO Tammy Furlong appointed President and Interim CEO, receives $600K transaction bonus at closing.
Stockholders approved reverse stock split (1:10–1:50), ratified auditor CohnReznick, and elected three Class I directors.
Tang Capital Partners provides limited guaranty up to $21.4M; support agreements covering ~5.1% of shares secured.

item 1.01 item 5.02 item 5.07 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Tammy Furlong

President and Interim Chief Executive Officer

Elevation Oncology, Inc.

Effective: 2025-06-30
Filed: June 9, 2025, 7:59 PM ET

Effective as of the Separation Date, the Board appointed Tammy Furlong, age 54, the Company’s Chief Financial Officer and Principal Financial and Accounting Officer, to succeed Mr. Ferra as President and Interim Chief Executive Officer

Departed (interim)

Joseph J. Ferra, Jr.

President, Chief Executive Officer

Elevation Oncology, Inc.

Effective: 2025-06-30
Successor: Tammy Furlong
Filed: June 9, 2025, 7:59 PM ET

In connection with the Merger, the Company terminated the employment of Joseph J. Ferra, Jr., as the Company’s President, Chief Executive Officer, effective as of June 30, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tammy Furlong was appointed as President and Interim Chief Executive Officer at Elevation Oncology, Inc..

Action: appointed
Role: President and Interim Chief Executive Officer

Exact text from the filing

Effective as of the Separation Date, the Board appointed Tammy Furlong, age 54, the Company’s Chief Financial Officer and Principal Financial and Accounting Officer, to succeed Mr. Ferra as President and Interim Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph J. Ferra, Jr. was terminated as President, Chief Executive Officer at Elevation Oncology, Inc..

Action: terminated
Role: President, Chief Executive Officer

Exact text from the filing

In connection with the Merger, the Company terminated the employment of Joseph J. Ferra, Jr., as the Company’s President, Chief Executive Officer, effective as of June 30, 2025

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-25-057620

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.